Kinetics and mechanism of nucleophilic displacements with heterocycles as leaving groups. Part 23. Studies at the borderlines between reactions proceeding (<i>i</i>) via free carbocations, (<i>ii</i>) via rate-determining formation of ion–molecule pairs, and (<i>iii</i>) via rate-determining nucleophilic attack on ion–molecule pairs
作者:Alan R. Katritzky、Bogumil Brycki
DOI:10.1139/v86-192
日期:1986.6.1
first-order reaction via nucleophilic trapping of intimate ion–molecule pairs and first-order reaction via the formation of free carbocations, both mechanisms proceed independently, without merging. Similarly at the borderline between first-order (rate-determining formation) and second-order (rate-determining nucleophilic attack) reactions of intimate ion–molecule pairs, both reactions again proceed
A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administraiton
A 2-amino-bicyclo[3.1.0] hexane-2,6-dicarboxylic ester derivative represented by formula [I]
[wherein R
1
and R
2
are identical or different, and each represents a hydrogen atom, a C
1-10
alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR
3
R
4
or the like (wherein R
3
and R
4
are identical or different, and each represents a hydrogen atom, a C
1-10
alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.
A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration
A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I]
[wherein R
1
and R
2
are identical or different, and each represents a hydrogen atom, a C
1-10
alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR
3
R
4
or the like (wherein R
3
and R
4
are identical or different, and each represents a hydrogen atom, a C
1-10
alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.
3-substituted-6-aryl pyridines of Formula I are provided:
wherein R
1
, R
2
, R
3
, R
8
, R
9
, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.
A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration
A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I]
[wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.